Cellanyx Publishes Details of Novel, First-in-Class Live Tumor Cell Phenotypic Test to Risk-Stratify Aggressive Vs. Indolent Disease Risk in Solid Tumors
Summary
“There is an urgent need for more precise cancer risk stratification tools,” said David Albala, MD, Chief of Urology at Crouse Hospital (Syracuse, NY) and an author on the paper.These methods, such as Gleason scoring for prostate cancer, lack precision in low and intermediate risk patients, leading to missed aggressive tumors, as well as over-diagnosis and over treatment of indolent disease.The Nature Biomedical Engineering paper reports the initial results from the analytical validation of the test from a multicenter, blinded clinical study of prostate tissue samples from patients who had undergone radical prostatectomies.Predictive metrics from the live tumor cell phenotypic analysis were compared with the conventional post-surgical adverse pathology findings to establish the sensitivity and specificity of the Cellanyx test.The company technology provides quantitative, actionable assessments of individual cancer cells in biopsy samples using multiple phenotypic biochemical and biophysical markers of tumor aggressiveness and metastatic potential.